TNGX

Tango Therapeutics, Inc.

Healthcare
Biotechnology
$3.87B market cap

Forecast run · Sep 14, 2026Upside rank 522 of 3,136

Model Signal

ForecastQ Daily Probabilities

55.2%

46.3%

36.3%

Analyst Consensus

Recommendation2.08/5 Buy

Last price$23.78

Price target$45.91

Implied move+93.1%

Analysts13

ForecastQ Portfolios

TNGX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.